Benzinga · Nov 11, 2026
Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $350
Barclays analyst Glen Santangelo maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and raises the price target from $345 to $350.

